Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 310

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 310
---
, to issue up to shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in
each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations, or restrictions thereon and to increase or decrease the number of shares of any such series, but not
below the number of shares of such series then outstanding.

Our board of directors may authorize the issuance of preferred stock with
voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate
purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and
other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.

Options

As of June 30, 2025, 12,992,582 shares of common stock were issuable upon the exercise of outstanding stock options, at a weighted-average
exercise price of $1.56 per share. For additional information regarding terms of our equity incentive plans, see the section titled “Executive Compensation—Equity Benefit Plans.”

Warrants

Class A Warrants

In November 2018 and March 2019, we issued warrants to certain investors to purchase an aggregate of 913,873 shares of our common stock at an
exercise price per share of $2.30, subject to adjustment as set forth in the warrant, or the Class A Warrants. In August 2023, in conjunction with the Series C financing, we modified the outstanding Class A Warrants and reduced the
exercise price to $0.01. As of June 30, 2025, Class A Warrants to purchase up to 695,961 shares of our common stock remained unexercised. The Class A Warrants include a cashless exercise feature allowing the holder to receive shares
underlying the applicable Class A Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of the applicable Class A Warrant for such shares. Each Class A Warrant is
exercisable until the 10 anniversary from its issuance date. The Class A Warrants include anti-dilution protection provisions, subject